US EditionAmgen: Biotech Pioneer's Dow Jones Journey
Summary by Disruption Banking
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amgen: Biotech Pioneer's Dow Jones Journey
Disruption Banking Amgen: Biotech Pioneer’s Dow Jones Journey In August 2020, S&P Dow Jones announced that Amgen (AMGN) would join the 30-stock Dow Jones Industrial Average (DJIA), replacing Pfizer. This move — prompted by Apple’s 4:1 stock split and a desire to diversify the index — added the first pure-play biotech and the sixth Nasdaq-listed firm to the Dow. Amgen’s inclusion was widely […] Artykuł Amgen: Biotech Pioneer’s Dow Jones Journey p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
